Abstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and the incidence of which is rising rapidly due to the increasing epidemic of obesity in both adults and children. The initial accumulation of fat followed by subsequent inflammation is central to the development of liver damage, and is critically influenced by host factors including age, gender, presence of diabetes, genetic polymorphisms and more recently by the gut microbiome. An increasing body of data suggest that NAFLD is also an independent risk factor of cardiovascular disease, which remains the commonest cause of mortality in such patients. This review focusses on the pathogenesis of NAFLD, and the evolution of new approaches to the management and treatment of NAFLD.
| Original language | English |
|---|---|
| Pages (from-to) | 192-202 |
| Number of pages | 11 |
| Journal | Atherosclerosis |
| Volume | 239 |
| Issue number | 1 |
| Early online date | 13 Jan 2015 |
| DOIs | |
| Publication status | Published - 1 Mar 2015 |
Keywords
- Non-alcoholic fatty liver disease
- Pathogenesis
- Dyslipidaemia
- Insulin resistance
- Cardiovascular disease
Access to Document
- Ni_Than_Newsome_Concise_review_non_alcoholic_fatty_liver_disease_Atherosclerosis_2015
NOTICE: this is the author’s version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Than NN, Newsome PN, A concise review of non-alcoholic fatty liver disease, Atherosclerosis (2015), doi: 10.1016/j.atherosclerosis.2015.01.001.